Most Read

A selective JAK inhibitor, Rinvoq is currently being analysed in various immune-mediated inflammatory diseases. Both the submissions are supported by the Phase III SELECT-AXIS 2 (Study 2) clinical

The partnership aims to develop new drugs with predictable manufacturing and clinical behaviour. Under the deal, Amgen will make an upfront investment of $50m for the first five

The latest move follows a collaboration and license agreement signed by the companies in November last year. Sold in the US under the brand name Nurtec ODT, rimegepant

An investigational antibody-drug conjugate (ADC), Teliso-V targets c-Met receptor tyrosine kinase that is overexpressed in tumours that include NSCLC. It is indicated to treat nonsquamous NSCLC patients with

The agreement also includes the lead candidate, OV350, which showed promising in-vitro and in-vivo proof of concept in resistant forms of epilepsy. The early-stage compound directly targets and

The production capacity of ritonavir oral tablets has been expanded to 100 million tablets per year and can also be increased further in future based on the market

AstraZeneca and Ionis Pharmaceuticals have closed a previously announced commercialisation agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. The deal was announced earlier this month.

The move comes after the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) for the vaccine, dubbed ‘The World’s COVID-19 Vaccine’. Corbevax technology was engineered

Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that hinders the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It increases the ability of the body’s